Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2017 1
2018 5
2019 3
2020 2
2021 8
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

20 results
Results by year
Filters applied: . Clear all
Page 1
Lokivetmab improved pruritus in a dog with cutaneous epitheliotropic lymphoma.
Inai K, Kitagawa K, Murakami M, Iwasaki T. Inai K, et al. J Vet Med Sci. 2022 Jan 7;84(1):36-39. doi: 10.1292/jvms.21-0346. Epub 2021 Dec 6. J Vet Med Sci. 2022. PMID: 34866072 Free article.
Despite long-term corticosteroid therapy, the patient's physiological (pruritus) and dermatological signs (alopecia, erythema, erosion, and ulceration with crust) progressed and showed no evidence of improvement. To address the worsening condition of pruritus, lokivetmab w …
Despite long-term corticosteroid therapy, the patient's physiological (pruritus) and dermatological signs (alopecia, erythema, erosion, and …
Onset and duration of action of lokivetmab in a canine model of IL-31 induced pruritus.
Fleck TJ, Norris LR, Mahabir S, Walters RR, Martinon O, Dunham SA, Gonzales AJ. Fleck TJ, et al. Vet Dermatol. 2021 Dec;32(6):681-e182. doi: 10.1111/vde.12943. Epub 2021 Apr 8. Vet Dermatol. 2021. PMID: 33830571
METHODS AND MATERIALS: Randomized, blinded, placebo-controlled studies were designed to evaluate the antipruritic properties of lokivetmab. Laboratory beagle dogs were given either placebo, 0.125, 0.5 or 2.0 mg/kg lokivetmab, subcutaneously. IL-31 then was administe …
METHODS AND MATERIALS: Randomized, blinded, placebo-controlled studies were designed to evaluate the antipruritic properties of lokivetma
Comparison of various treatment options for canine atopic dermatitis: a blinded, randomized, controlled study in a colony of research atopic beagle dogs.
Marsella R, Ahrens K, Wilkes R, Trujillo A, Dorr M. Marsella R, et al. Vet Dermatol. 2020 Aug;31(4):284-e69. doi: 10.1111/vde.12849. Epub 2020 Apr 17. Vet Dermatol. 2020. PMID: 32301565
HYPOTHESIS/OBJECTIVES: To compare prednisone, oclacitinib, ciclosporin and lokivetmab treatment of atopic dermatitis. ANIMALS: Nineteen atopic beagle dogs. ...CONCLUSIONS AND CLINICAL IMPORTANCE: Lokivetmab prevented flares when given before challenge. Oclacitinib a …
HYPOTHESIS/OBJECTIVES: To compare prednisone, oclacitinib, ciclosporin and lokivetmab treatment of atopic dermatitis. ANIMALS: Ninete …
Lokivetmab therapy for pruritus in a dog with cutaneous mastocytosis.
Meichner K, Kiupel M, Kasantikul T, Rakich P, Banovic F. Meichner K, et al. Vet Dermatol. 2019 Feb;30(1):73-e22. doi: 10.1111/vde.12702. Epub 2018 Nov 26. Vet Dermatol. 2019. PMID: 30479052
Treatment was initiated with anti-canine-interleukin (IL)-31 monoclonal antibody lokivetmab; antihistamines were continued. The dog's pruritus resolved within seven days and was maintained in remission over 15 months with once monthly lokivetmab injections; the skin …
Treatment was initiated with anti-canine-interleukin (IL)-31 monoclonal antibody lokivetmab; antihistamines were continued. The dog's …
In vitro evaluation of potential interference of lokivetmab with protein electrophoresis and immunofixation.
Apostolopoulos N, Mitropoulou A, Foerster G, Failing K, Moritz A, Mayer U. Apostolopoulos N, et al. Tierarztl Prax Ausg K Kleintiere Heimtiere. 2021 Aug;49(4):278-283. doi: 10.1055/a-1519-3587. Epub 2021 Aug 23. Tierarztl Prax Ausg K Kleintiere Heimtiere. 2021. PMID: 34425606 English.
This triggers concerns for similar misdiagnoses in animals treated with monoclonal antibodies. The aim of this study was to evaluate if lokivetmab interferes with serum protein electrophoresis and immunofixation electrophoresis in dogs. ...The residual sera were analysed w …
This triggers concerns for similar misdiagnoses in animals treated with monoclonal antibodies. The aim of this study was to evaluate if l
Weekly topical therapy based on plant extracts combined with lokivetmab in canine atopic dermatitis.
Bensignor E, Videmont E. Bensignor E, et al. Vet Dermatol. 2022 Feb;33(1):68-e22. doi: 10.1111/vde.13004. Epub 2021 Aug 19. Vet Dermatol. 2022. PMID: 34414621
BACKGROUND: Lokivetmab is an effective treatment for atopic dermatitis (AD) in dogs. ...A longer-lasting remission was noted in Group B compared to Group A; dogs receiving the combined treatment showed an extended time to flare compared to dogs treated with lokivetmab
BACKGROUND: Lokivetmab is an effective treatment for atopic dermatitis (AD) in dogs. ...A longer-lasting remission was noted in Group …
Evaluation of the clinical efficiency of lokivetmab in client privately owned atopic dogs - multicenter study.
Szczepanik MP, Popiel J, Cekiera A, Pomorska-Handwerker D, Karaś-Tęcza J, Ściskalska M, Oczkowska K, Taube M, Olender V, Parys P. Szczepanik MP, et al. Pol J Vet Sci. 2020 Jun;23(2):191-195. doi: 10.24425/pjvs.2020.132765. Pol J Vet Sci. 2020. PMID: 32627992
AD can be treated using allergenspecific immunotherapy as well as symptomatic antipruritic treatment including the use of lokivetmab - caninized anti-interleukine-31 antibody.The aim of the study was to evaluate the effectiveness of lokivetmab over 12 weeks of treat …
AD can be treated using allergenspecific immunotherapy as well as symptomatic antipruritic treatment including the use of lokivetmab
A masked, randomised clinical trial evaluating the efficacy and safety of lokivetmab compared to saline control in client-owned dogs with allergic dermatitis.
Van Brussel L, Moyaert H, Escalada M, Mahabir SP, Stegemann MR. Van Brussel L, et al. Vet Dermatol. 2021 Oct;32(5):477-e131. doi: 10.1111/vde.12984. Epub 2021 Jun 27. Vet Dermatol. 2021. PMID: 34180084 Free PMC article.
HYPOTHESIS/OBJECTIVES: To demonstrate the efficacy and safety of lokivetmab (canine anti-IL-31 monoclonal antibody) for treatment of pruritus associated with allergic dermatitis in dogs. ...For all time points, investigator-assessed VAS means were significantly reduced in …
HYPOTHESIS/OBJECTIVES: To demonstrate the efficacy and safety of lokivetmab (canine anti-IL-31 monoclonal antibody) for treatment of …
A retrospective analysis of the use of lokivetmab in the management of allergic pruritus in a referral population of 135 dogs in the western USA.
Souza CP, Rosychuk RAW, Contreras ET, Schissler JR, Simpson AC. Souza CP, et al. Vet Dermatol. 2018 Dec;29(6):489-e164. doi: 10.1111/vde.12682. Epub 2018 Aug 23. Vet Dermatol. 2018. PMID: 30141223
BACKGROUND: Lokivetmab neutralizes IL-31, a cytokine that plays an important role in the pathogenesis of atopic dermatitis (AD) in dogs. ...There were no significant associations between treatment success and age of onset of clinical signs, disease chronicity, lokivetma
BACKGROUND: Lokivetmab neutralizes IL-31, a cytokine that plays an important role in the pathogenesis of atopic dermatitis (AD) in do …
20 results